Hoffmann-la Roche Inc.

Moritz Rapp

Christian Klein

Peter Bruenker

Harald Duerr

Alexander Bujotzek

Christine Trumpfheller

Pablo Umana

Joerg Zielonka

Marine Le Clech

Guy Georges

Pablo Umaña

Stephane Leclair

Eva Carina Sum

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-FAP clone 212

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

Growing community of inventors

Zurich, Switzerland

Moritz Rapp